Breaking News Instant updates and real-time market news.

CVS

CVS Health

$63.82

-6.1 (-8.72%)

, LUV

Southwest

$54.63

-3.03 (-5.25%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CVS Health (CVS) downgraded to Market Perform from Outperform at Wells Fargo with analyst Peter Costa citing its "continued failure" to stabilize its existing businesses, particularly the long-term care business, after two years of pressure. 2. Southwest (LUV) downgraded to Sell from Neutral at Goldman Sachs with analyst Catherine O'Brien saying Southwest's fiscal 2019 pretax margin will decline 60 basis points due to the dilutive impact of its new Hawaii flying and unit cost ex-fuel pressures. 3. Charles Schwab (SCHW) downgraded to Sell from Neutral at UBS, while E-Trade (ETFC) was downgraded to Neutral from Buy. 4. Palo Alto Networks (PANW) downgraded to Hold from Buy at Gabelli with analyst Hendi Susanto citing valuation. 5. Teva (TEVA) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying her investment thesis is "broken" after Teva's "disappointing 2019 guidance and cautious longer-term outlook." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

CVS

CVS Health

$63.82

-6.1 (-8.72%)

LUV

Southwest

$54.63

-3.03 (-5.25%)

SCHW

Charles Schwab

$45.95

-1.11 (-2.36%)

ETFC

E-Trade

$48.05

-0.61 (-1.25%)

PANW

Palo Alto Networks

$228.77

-1.42 (-0.62%)

TEVA

Teva

$17.40

-0.61 (-3.39%)

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 27

    Feb

  • 04

    Mar

  • 05

    Mar

CVS CVS Health
$63.82

-6.1 (-8.72%)

02/20/19
WELS
02/20/19
DOWNGRADE
WELS
Market Perform
CVS Health downgraded to Market Perform from Outperform at Wells Fargo
02/07/19
MSCO
02/07/19
NO CHANGE
Target $100
MSCO
Overweight
CVS shares could rise 4%-9% on 'good enough' guidance, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser noted that CVS Health will provide guidance on February 20 for the first time since completing the Aetna transaction and he puts 60% odds on initial FY19 EPS guidance of $7.00-$7.30. While such an outlook would be below the current consensus of $7.44, bears are concerned guidance could be below $7 and such an outlook would be seen as "good enough" to drive the stock up 4%-9%, Goldwasser tells investors. If initial 2019 EPS guidance is below $7.00, which is a scenario he gives a 30% probability, the stock could be down 11%. If the initial 2019 EPS guidance range has a midpoint above $7.40, which Goldwasser assigns only 10% odds of happening, the stock could be up 10%, the analyst said. He keeps an Overweight rating and $100 price target on CVS shares ahead of the company's December quarter earnings report.
01/31/19
MSCO
01/31/19
NO CHANGE
Target $391
MSCO
Overweight
Anthem price target raised to $391 from $372 at Morgan Stanley
Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating.
02/20/19
WELS
02/20/19
DOWNGRADE
Target $68
WELS
Market Perform
Wells Fargo downgrades CVS Health to Market Perform, slashes price target to $68
As previously reported, Wells Fargo analyst Peter Costa downgraded CVS Health to Market Perform from Outperform based on its "continued failure" to stabilize its existing businesses, particularly the long-term care business, after two years of pressure. Beyond the "obvious need" to integrate the Aetna acquisition, CVS expects the ongoing business pressures to have an outsized impact on 2019, making it a transition year, said Costa, who called the company's 2019 adjusted EPS guidance of $6.68-$6.88 "disappointing." He lowered his 2019 EPS estimate to $6.78 and cut his price target on CVS Health shares to $68 from $104.
LUV Southwest
$54.63

-3.03 (-5.25%)

02/20/19
GSCO
02/20/19
DOWNGRADE
Target $54
GSCO
Sell
Goldman downgrades Southwest Airlines to Sell, prefers Alaska Air
Goldman Sachs analyst Catherine O'Brien downgraded Southwest Airlines (LUV) to Sell from Neutral and lowered her price target for the shares to $54 from $66. Southwest's fiscal 2019 pretax margin will decline 60 basis points due to the dilutive impact of its new Hawaii flying and unit cost ex-fuel pressures, O'Brien tells investors in a research note. With the analyst forecasting most of her coverage universe to see margin expansion in 2019, she expects Southwest shares to underperform this year. O'Brien continues to be positive on the company's long-term thesis, but prefers shares of Alaska Air (ALK) at this time. She expects Alaska to see greater than industry average margin expansion in 2019.
02/19/19
GSCO
02/19/19
DOWNGRADE
Target $54
GSCO
Sell
Southwest downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Catherine O'Brien downgraded Southwest Airlines to Sell and lowered her price target for the shares to $54 from $66. The analyst expects Southwest's Hawaii launch to pressure its margins in the near-term.
02/04/19
VERT
02/04/19
INITIATION
Target $70
VERT
Buy
Southwest initiated with a Buy at Vertical Research
Vertical Research analyst Darryl Genovesi started Southwest earlier with a Buy rating and $70 price target.
01/25/19
DBAB
01/25/19
DOWNGRADE
Target $35
DBAB
Hold
Deutsche downgrades Hawaiian Holdings ahead of Southwest competition
Deutsche Bank analyst Michael Linenberg downgraded Hawaiian Holdings (HA) to Hold from Buy and cut his price target for the shares to $35 from $41. The analyst sees a more challenging competitive backdrop in Hawaiian's core markets by the June quarter. The fact that Southwest (LUV) could be serving inter-island within a few months of its inaugural transpacific flight "could be problematic for Hawaiian," Linenberg tells investors in a research note.
SCHW Charles Schwab
$45.95

-1.11 (-2.36%)

02/20/19
UBSW
02/20/19
DOWNGRADE
Target $42
UBSW
Sell
Charles Schwab downgraded to Sell from Neutral at UBS
UBS analyst Brennan Hawken downgraded Charles Schwab to Sell and lowered his price target for the shares to $42 from $48. The analyst sees revenue headwinds at the same time as risk to upward pressure on expenses. This will lead to earnings and multiple compression, Hawken tells investors in a research note. The analyst believes Schwab's revenue guidance, which assumes a mid-year rate hike and higher daily average revenue trades, is aggressive against the current backdrop. Expectations may be too high and could put the stock at risk, particularly since buybacks are likely not enough to "cushion the blow to the growth story," Hawken contends.
01/29/19
MSCO
01/29/19
NO CHANGE
MSCO
Overweight
Morgan Stanley sees 'more to come' from discount brokers after strong Q4
Morgan Stanley analyst Michael Cyprys said the "strong" Q4 earnings reports from Charles Schwab (SCHW), E-Trade (ETFC) and TD Ameritrade (AMTD) showed that the discount brokers can grow revenues in a volatile, late-cycle backdrop. He increased his 2020 top-line estimates across the group, citing expectations for higher net interest margins and higher cash balances. Cyprys, who said the valuations in the group remain compelling on both an absolute and relative basis, keeps Overweight ratings on all three stocks mentioned. He raised his price target on Charles Schwab to $57 from $55, on E-Trade to $62 from $61 and on TD Ameritrade to $64 from $59.
01/22/19
MSCO
01/22/19
NO CHANGE
Target $57
MSCO
Overweight
Charles Schwab target raised to $57 ahead of winter update at Morgan Stanley
Morgan Stanley analyst Michael Cyprys said he has increased conviction in Charles Schwab (SCHW) shares after the company saw stronger organic deposit growth and broadly strong underlying growth metrics in Q4. He expects Charles Schwab to provide2019 guidance at the company's upcoming Winter Update on February 5 that should meet consensus expectations, but he also expects Schwab to beat those expectations over the course of 2019, as they havve done in prior years. He also expects Charles Schwab to give "more rational" pricing commentary this late in the cycle, which should support the stock and peers TD Ameritrade (AMTD) and E-Trade (ETFC), Cyprys tells investors. He raised his price target on Charles Schwab shares to $57 from $55 ahead of the update call and keeps an Overweight rating on the stock.
01/16/19
RAJA
01/16/19
NO CHANGE
Target $54
RAJA
Outperform
Charles Schwab price target raised to $54 from $51 at Raymond James
Raymond James analyst Patrick O'Shaughnessy raised his price target on Charles Schwab shares to $54 from $51 following the company's report of its Q4 results. He expects Schwab's ability to attract new client accounts and assets to drive continued revenue growth, even in the absence of further rate hikes, O'Shaughnessy tells investors. He keeps an Outperform rating on the stock.
ETFC E-Trade
$48.05

-0.61 (-1.25%)

02/20/19
UBSW
02/20/19
DOWNGRADE
Target $51
UBSW
Neutral
E-Trade downgraded to Neutral from Buy at UBS
UBS analyst Brennan Hawken downgraded E-Trade Financial to Neutral and lowered his price target for the shares to $51 from $58. The analyst wonders what catalysts could move the shares "materially higher" amid "mounting cyclical concerns." He cites the "extended time frame tied to current targets" and a low likelihood of a strategic transaction as the reasons for the downgrade. He sees "more compelling places to allocate capital."
01/25/19
LEHM
01/25/19
NO CHANGE
Target $55
LEHM
Overweight
E-Trade price target raised to $55 from $52 at Barclays
Barclays analyst Jeremy Campbell raised his price target for E-Trade Financial to $55 following the company's Q4 results and keeps an Overweight rating on the shares.
PANW Palo Alto Networks
$228.77

-1.42 (-0.62%)

02/20/19
GABE
02/20/19
DOWNGRADE
GABE
Gabelli downgrades Palo Alto Networks to Hold on valuation
Gabelli analyst Hendi Susanto last night downgraded Palo Alto Networks to Hold from Buy. The analyst cites valuation for the downgrade, pointing out the shares have appreciated from $176 per share, when he published his latest Buy recommendation, to about $230 per share currently. The stock now trades near the analyst's July fiscal 2020 private market value estimate of $227 per share. Susanto, however, continues to maintain a favorable view of Palo Alto's "market leadership, technology platform, and competitive security platform."
02/19/19
GABE
02/19/19
DOWNGRADE
GABE
Hold
Palo Alto Networks downgraded to Hold from Buy at Gabelli
Gabelli analyst Hendi Susanto downgraded Palo Alto Networks to Hold from Buy.
02/20/19
OPCO
02/20/19
NO CHANGE
Target $270
OPCO
Outperform
Palo Alto Networks price target raised to $270 from $250 at Oppenheimer
Oppenheimer analyst Shaul Eyal raised his price target for Palo Alto Networks to $270 from $250 and reiterated an Outperform rating on the shares. Ahead of Q2 results, his post-quarter checks with 22 VARs suggest that the company's Q2 revenue could come ahead of Street expectations, RedLock multi-cloud security deployment is gradually realizing interest and traction, appliances could generate additional upside to Product revenue estimates, customers' ongoing cloud migration strategies could support healthy subscription growth, and highly achievable estimates.
02/19/19
JEFF
02/19/19
NO CHANGE
Target $249
JEFF
Buy
Demisto 'strategic and complementary' to Palo Alto Networks, says Jefferies
After Palo Alto Networks announced its intent to acquire security, orchestration, automation, and response company Demisto for $560M in cash and stock, Jefferies analyst John DiFucci said he views this as a "strategic and complementary" deal that positions Palo Alto in the emerging "SOAR" market. However, he noted that one of Demisto's key assets is its ability to integrate with a variety of vendors and be vendor neutral and he questions this neutrality going forward with the company now being part of Palo Alto. DiFucci, who views orchestration solutions as gaining in utility and relevance, keeps a Buy rating on Palo Alto Networks shares.
TEVA Teva
$17.40

-0.61 (-3.39%)

02/14/19
WELS
02/14/19
NO CHANGE
Target $20
WELS
Outperform
Teva price target lowered to $20 from $24 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Teva Pharmaceutical to $20 from $24 and keeps a Market Perform rating on the shares following yesterday's Q4 results. The outlook for 2019, while negative and worse than consensus expectations, looks, in many ways, overly conservative, Maris tells investors in a research note titled "Things Are Bad, Guidance Worse." The analyst thinks Teva has guided to ranges that are realistic and potentially beatable, but he admits this is "not an easy task." Maris sees 2019 as "relatively de-risked" with guidance coming in below his expectations. However, the stock's overall valuation is "not very compelling," he adds. The analyst believes the stock offers some upside potential, "but not enough to justify an upgrade at this point."
02/14/19
02/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) double upgraded to Outperform from Underperform at Macquarie with analyst David Hewitt saying with a "world class" Guyana play, multiple liquefied natural gas developments, the Permian "juggernaut" and growth in the integrated downstream, Exxon is "well positioned for the future, and is not being overly distracted by the energy transition debate." 2. Synchrony (SYF) upgraded to Buy from Neutral at Goldman Sachs with analyst Ryan Nash saying with shares trading at a discount to peers due to credit-related concerns, the current valuation is "compelling." 3. Teva (TEVA) upgraded to Outperform from Market Perform at Raymond James. 4. Elevate Credit (ELVT) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying he views the shares as "simply too inexpensive" at current levels. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/14/19
FBCO
02/14/19
NO CHANGE
Target $20
FBCO
Neutral
Teva price target lowered to $20 from $26 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Teva to $20 from $26 as first-time 2019 guidance was clearly well below expectations across a number of line items and not surprisingly put significant pressure on the stock. Although the analyst thinks the sharp selloff may be somewhat overdone and 2019 guidance could prove to be conservative, he reiterates a Neutral rating as the focus shifts from a restructuring story to a growth one where his growth expectations are below that of the company.
02/20/19
MZHO
02/20/19
DOWNGRADE
Target $18
MZHO
Neutral
Teva downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Teva Pharmaceutical to Neutral and lowered her price target for the shares to $18 from $25. The analyst says her investment thesis is "broken" after Teva's "disappointing 2019 guidance and cautious longer-term outlook." The company's cost-cutting and deleveraging will take longer than expected, Koffler tells investors in a research note. Without any key data readouts this year, Koffler sees few growth catalysts for Teva in 2019.

TODAY'S FREE FLY STORIES

03:10
09/23/19
09/23
03:10
09/23/19
03:10
General news
FX Update: The pound has come under modest pressure »

FX Update: The pound has…

01:55
09/23/19
09/23
01:55
09/23/19
01:55
General news
FX Action: »

FX Action: Soothing tones…

01:55
09/23/19
09/23
01:55
09/23/19
01:55
General news
Fedspeak preview: »

Fedspeak preview:…

01:45
09/23/19
09/23
01:45
09/23/19
01:45
General news
Mideast tensions keep oil prices underpinned. »

Mideast tensions keep oil…

01:30
09/23/19
09/23
01:30
09/23/19
01:30
General news
Asian Market Wrap: »

Asian Market Wrap: Asian…

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:35
09/22/19
09/22
19:35
09/22/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

BNPQY

BNP Paribas

$0.00

(0.00%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

ENDP

Endo

$3.48

0.115 (3.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ABT

Abbott

$83.56

0.35 (0.42%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

MYL

Mylan

$21.01

0.03 (0.14%)

MCK

McKesson

$146.83

1.06 (0.73%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

WAB

Wabtec

$74.01

0.26 (0.35%)

CVS

CVS Health

$64.28

0.65 (1.02%)

REAL

RealReal

$17.00

0.21 (1.25%)

CMG

Chipotle

$835.17

3.67 (0.44%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 15

    Oct

  • 16

    Oct

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

BGNE

BeiGene

$135.62

2.61 (1.96%)

19:34
09/22/19
09/22
19:34
09/22/19
19:34
Hot Stocks
BeiGene announces results on Tislelizumab from ongoing clinical trials »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 15

    Oct

  • 27

    Feb

CE

Celanese

$122.73

-1.06 (-0.86%)

19:24
09/22/19
09/22
19:24
09/22/19
19:24
Hot Stocks
Celanese experiences emergency incident at Clear Lake facility »

Celanese experienced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$379.33

-5.28 (-1.37%)

19:21
09/22/19
09/22
19:21
09/22/19
19:21
Periodicals
Indonesia to fault 737 Max design, oversight lapses in Lion Air crash, WSJ says »

Indonesian investigators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa rating change at Goldman Sachs »

Alcoa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

, SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa downgraded to Neutral from Buy at Goldman Sachs »

Goldman Sachs analyst…

AA

Alcoa

$21.70

-0.26 (-1.18%)

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

19:08
09/22/19
09/22
19:08
09/22/19
19:08
Downgrade
Commercial Metals rating change at Goldman Sachs »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:06
09/22/19
09/22
19:06
09/22/19
19:06
Downgrade
Schnitzer Steel rating change at Goldman Sachs »

Schnitzer Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNSR

Finisar

$24.31

1.25 (5.42%)

18:15
09/22/19
09/22
18:15
09/22/19
18:15
Hot Stocks
Finisar presents new products, technologies at ECOC 2019 »

Finisar introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

, DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

18:04
09/22/19
09/22
18:04
09/22/19
18:04
Periodicals
Deutsche Bank nearing deal to transfer prime assets to BNP, Reuters says »

Deutsche Bank (DB) is…

BNPQY

BNP Paribas

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$158.47

-0.21 (-0.13%)

18:00
09/22/19
09/22
18:00
09/22/19
18:00
Initiation
Verisk Analytics initiated at Keefe Bruyette »

Verisk Analytics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.92

0.78 (2.10%)

, CMCSA

Comcast

$46.36

-0.32 (-0.69%)

16:58
09/22/19
09/22
16:58
09/22/19
16:58
On The Fly
Box Office Battle: 'Downton Abbey' wins weekend with $31M »

"Box Office Battle" is…

T

AT&T

$37.92

0.78 (2.10%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.19

-0.19 (-0.32%)

LGF.A

Lionsgate

$9.49

-0.47 (-4.72%)

LGF.B

Lionsgate

$8.88

-0.435 (-4.67%)

DIS

Disney

$132.18

-1.14 (-0.86%)

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

VIVHY

Vivendi

$0.00

(0.00%)

, MDSO

Medidata

$91.77

-0.04 (-0.04%)

16:01
09/22/19
09/22
16:01
09/22/19
16:01
Periodicals
Vivendi to widen legal battle against Mediaset beyond Italy, Reuters says »

Vivendi (VIVHY) is taking…

VIVHY

Vivendi

$0.00

(0.00%)

MDSO

Medidata

$91.77

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:57
09/22/19
09/22
15:57
09/22/19
15:57
Periodicals
Some WeWork board members seeing to remove Neumann as CEO, WSJ says »

A bloc of WeWork…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:54
09/22/19
09/22
15:54
09/22/19
15:54
Periodicals
SoftBank turns against WeWork's parent CEO, Reuters reports »

SoftBank (SFTBY), the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$24.92

-0.28 (-1.11%)

, VIA

Viacom

$26.67

-0.85 (-3.09%)

15:48
09/22/19
09/22
15:48
09/22/19
15:48
Hot Stocks
Viacom acquires exclusive cable rights to Seinfeld from Sony Pictures Television »

Viacom (VIAB, VIA)…

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

SNE

Sony

$59.19

-0.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

PWR

Quanta Services

$37.61

-0.28 (-0.74%)

12:22
09/22/19
09/22
12:22
09/22/19
12:22
Conference/Events
Quanta Services management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

PTEN

Patterson-UTI

$9.66

0.01 (0.10%)

12:21
09/22/19
09/22
12:21
09/22/19
12:21
Conference/Events
Patterson-UTI management to meet with Stephens »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ESE

Esco Technologies

$78.44

-1.54 (-1.93%)

12:19
09/22/19
09/22
12:19
09/22/19
12:19
Conference/Events
Esco Technologies management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CSGP

CoStar Group

$595.10

-3.87 (-0.65%)

12:16
09/22/19
09/22
12:16
09/22/19
12:16
Conference/Events
CoStar Group participates in a conference call with Stephens »

Conference call with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.